403 related articles for article (PubMed ID: 35429398)
1. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
[TBL] [Abstract][Full Text] [Related]
2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
3. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
5. Omicron infection increases IgG binding to spike protein of predecessor variants.
Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
[TBL] [Abstract][Full Text] [Related]
6. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
Front Immunol; 2022; 13():946318. PubMed ID: 35928813
[TBL] [Abstract][Full Text] [Related]
7. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients.
Hastert FD; Henss L; von Rhein C; Gerbeth J; Wieters I; Borgans F; Khodamoradi Y; Zacharowski K; Rohde G; Vehreschild MJGT; Schnierle BS
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632624
[TBL] [Abstract][Full Text] [Related]
11. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
13. Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.
Schulz SR; Hoffmann M; Roth E; Pracht K; Burnett DL; Mazigi O; Schuh W; Manger B; Mielenz D; Goodnow CC; Christ D; Pöhlmann S; Jäck HM
Eur J Immunol; 2022 Jun; 52(6):970-977. PubMed ID: 35253229
[TBL] [Abstract][Full Text] [Related]
14. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
15. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
16. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
17. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
[TBL] [Abstract][Full Text] [Related]
18. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
Liu J; Chandrashekar A; Sellers D; Barrett J; Jacob-Dolan C; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
Nature; 2022 Mar; 603(7901):493-496. PubMed ID: 35102312
[TBL] [Abstract][Full Text] [Related]
19. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
20. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S; Arashiro T; Adachi Y; Moriyama S; Kinoshita H; Kanno T; Saito S; Katano H; Iida S; Ainai A; Kotaki R; Yamada S; Kuroda Y; Yamamoto T; Ishijima K; Park ES; Inoue Y; Kaku Y; Tobiume M; Iwata-Yoshikawa N; Shiwa-Sudo N; Tokunaga K; Ozono S; Hemmi T; Ueno A; Kishida N; Watanabe S; Nojima K; Seki Y; Mizukami T; Hasegawa H; Ebihara H; Maeda K; Fukushi S; Takahashi Y; Suzuki T
Med; 2022 Apr; 3(4):249-261.e4. PubMed ID: 35261995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
